• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4605582)   Today's Articles (17)   Subscriber (49373)
For: Dardano A, Bianchi C, Del Prato S, Miccoli R. Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag 2014;10:465-75. [PMID: 25143741 PMCID: PMC4132254 DOI: 10.2147/vhrm.s40097] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]  Open
Number Cited by Other Article(s)
1
Niu YL, Zhang Y, Song ZY, Zhao CZ, Luo Y, Wang Y, Yuan J. Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. IRANIAN JOURNAL OF PUBLIC HEALTH 2024;53:313-322. [PMID: 38894842 PMCID: PMC11182486 DOI: 10.18502/ijph.v53i2.14916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 09/18/2023] [Indexed: 06/21/2024]
2
Oner H, Gunhan HG, Gogas Yavuz D. Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience. FRONTIERS IN CLINICAL DIABETES AND HEALTHCARE 2022;3:783277. [PMID: 36992737 PMCID: PMC10012153 DOI: 10.3389/fcdhc.2022.783277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/25/2021] [Accepted: 05/09/2022] [Indexed: 06/19/2023]
3
Pan K, Shi X, Liu K, Wang J, Chen Y. Efficacy, Pharmacokinetics, Biodistribution and Excretion of a Novel Acylated Long-Acting Insulin Analogue INS061 in Rats. Drug Des Devel Ther 2021;15:3487-3498. [PMID: 34408401 PMCID: PMC8364340 DOI: 10.2147/dddt.s317327] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Accepted: 07/23/2021] [Indexed: 12/17/2022]  Open
4
Onder CE, Kuşkonmaz SM, Koc G, Firat S, Omma T, Taskaldiran I, Gokbulut P, Culha C. Factors that affect the Glycemic Control Achieved by Switching to Insulin Degludec/ Aspart in Insulin-Treated Patients with Type 1 and Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study. ACTA ENDOCRINOLOGICA-BUCHAREST 2021;16:443-448. [PMID: 34084235 DOI: 10.4183/aeb.2020.443] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
5
Haluzík M, Fulcher G, Pieber TR, Bardtrum L, Tutkunkardas D, Rodbard HW. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. Diabetes Obes Metab 2018;20:1585-1592. [PMID: 29451706 PMCID: PMC6033009 DOI: 10.1111/dom.13261] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 02/09/2018] [Accepted: 02/12/2018] [Indexed: 01/17/2023]
6
Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1). Diabet Med 2017;34:167-173. [PMID: 26773446 PMCID: PMC5248618 DOI: 10.1111/dme.13068] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/11/2016] [Indexed: 01/25/2023]
7
Rodbard HW, Cariou B, Pieber TR, Endahl LA, Zacho J, Cooper JG. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial. Diabetes Obes Metab 2016;18:274-80. [PMID: 26592732 PMCID: PMC5066701 DOI: 10.1111/dom.12609] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Revised: 11/13/2015] [Accepted: 11/16/2015] [Indexed: 01/12/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA